Bicara Therapeutics Inc. (BCAX) – What Are Investment Firms Saying About This Stock?

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned an average rating of “Moderate Buy” from the sixteen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $32.64.

Several equities research analysts recently issued reports on BCAX shares. Citigroup reiterated a “market outperform” rating on shares of Bicara Therapeutics in a research note on Friday, August 21st. Wedbush upped their price objective on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. BMO Capital Markets initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price objective for the company. Morgan Stanley raised their target price on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a report on Thursday, September 10th.

Bicara Therapeutics Stock Up 0.1%

Shares of BCAX opened at $17.34 on Wednesday. The company has a 50 day moving average of $22.25 and a 200-day moving average of $23.18. Bicara Therapeutics has a twelve month low of $13.70 and a twelve month high of $30.99. The stock has a market capitalization of $1.15 billion, a P/E ratio of -5.59 and a beta of -0.70.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, meeting the consensus estimate of ($0.82). On average, sell-side analysts anticipate that Bicara Therapeutics will post -3.49 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Ivan Hyep sold 12,500 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.97, for a total transaction of $349,625.00. Following the sale, the chief financial officer directly owned 129,855 shares in the company, valued at approximately $3,632,044.35. The trade was a 8.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Cohlhepp sold 17,500 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total value of $400,750.00. Following the sale, the chief executive officer owned 181,641 shares in the company, valued at approximately $4,159,578.90. This trade represents a 8.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 58,750 shares of company stock valued at $1,554,800. 13.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors have recently added to or reduced their stakes in BCAX. Engineers Gate Manager LP bought a new stake in shares of Bicara Therapeutics in the second quarter worth $499,000. Arizona State Retirement System acquired a new stake in Bicara Therapeutics in the second quarter valued at $241,000. Allianz Asset Management GmbH bought a new position in Bicara Therapeutics during the 2nd quarter worth $511,000. Corient Private Wealth LP bought a new position in Bicara Therapeutics during the 2nd quarter worth $1,089,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in Bicara Therapeutics during the 2nd quarter worth $272,000.

About Bicara Therapeutics

Bicara Therapeutics Inc (NASDAQ: BCAX) is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to address both cancer cells and the tumor microenvironment, which can suppress immune responses and limit the effectiveness of existing treatments.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. It is an investigational bifunctional fusion protein designed to target the epidermal growth factor receptor (EGFR) on tumor cells while blocking transforming growth factor beta (TGF-β), a signaling pathway associated with tumor growth and immune suppression.